Relapsed/refractory non-Hodgkin lymphoma
Clinical trials for Relapsed/refractory non-Hodgkin lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory non-Hodgkin lymphoma trials appear
Sign up with your email to follow new studies for Relapsed/refractory non-Hodgkin lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphomas: experimental drug targets cancer protein
Disease control Recruiting nowThis study tests a new drug called BMS-986458, which works by breaking down a protein that helps lymphoma cells grow. It is being tested alone or with other lymphoma drugs in people whose non-Hodgkin lymphoma has returned or not responded to prior treatments. The trial aims to fi…
Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…
Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Phase 2/3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC